Presentation of the Phase II trial final results of HER-Vaxx, a B cell peptide-based Her-2/neu vaccine (Tobias et al, 2017, Wiedermann et al, 2021), at AACR Annual Meeting 2024

Oops, an error occurred! Request: 1ffd5f3dd6416